Skip to NavigationSkip to content

prostate cancer

Prostate Cancer ‘super responders’ could live for two more years on Keytruda

Men with advanced prostate cancer, who have exhausted all treatment options, could use the immunotherapy Keytruda (pembrolizumab) to live for another two years or more.

A major clinical trial showed that a small proportion of men were ‘super responders’ and were alive and well even after the trial had ended, despite having had a very poor prognosis before treatment.

Sanofi's Jevtana doubles progression-free survival in metastatic castration-resistant prostate cancer

Sanofi was present at the 2019 European Society of Medical Oncology (ESMO) Congress in Barcelona this year to reveal new data showing that its microtubule inhibitor Jevtana (cabazitaxel) met its primary endpoint in the treatment of metastatic castration-resistant prostate cancer (mCRPC) when combined with prednisone.

It was shown that the combo more than doubled radiographic progression free survival (rPFS) to a median of eight months, compared to 3.7 months with abiraterone or enzalutamide, clearing the primary endpoint of the study.

FDA expands Janssen's Erleada label to cover metastatic castration-sensitive prostate cancer

Janssen has announced that the FDA has expanded the label of its androgen receptor inhibitor Erleada (apalutamide) to include the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

The therapy was evaluated under Priority Review Designation through the US regulator’s Real-Time Oncology Review programme. It is estimated that around 40,000 new diagnoses of mCSPC are made in the US each year.

AstraZeneca's Lynparza meets primary endpoint in Phase 3 prostate cancer trial

AstraZeneca’s PARP inhibitor Lynparza was successful in improving progression free survival in a Phase 3 trial of patients with metastatic prostate cancer.

The drug met its primary endpoint in the Phase 3 PROfound  trial of men with metastatic castration-resistant prostate cancer (mCRPC) who have a *homologous recombination repair gene mutation (HRRm) and have progressed on prior treatment with new hormonal anticancer treatments (e.g. enzalutamide and abiraterone).

Bayer and Orion's Nubeqa secures FDA approval in non-metastatic castration-resistant prostate cancer

The FDA has awarded approval under its Priority Review pathway to Nubeqa (darolutamide) for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC), it has emerged.

The decision to authorise the non-steroidal androgen receptor inhibitor (ARi), which is jointly developed by Orion and Bayer, was based on Phase 3 data which demonstrated that Nubeqa, in combination with androgen deprivation therapy (ADT), improved metastasis-free survival by a median of 40.4 months compared to 18.4 months with placebo plus ADT, meeting its primary endpoint.

New urine test can diagnose and offer prognosis for prostate cancer

A new urine test can diagnose cases of aggressive prostate cancer more quickly than invasive biopsies.

The test can also offer prognostic information to men on active surveillance (AS) the management option for those men with localised prostate cancer in which the cancer is not treated straight away.

Janssen's Erleada combo smashes endpoints in advanced hormone-sensitive prostate cancer

Janssen joined the showing at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago to present new data for its androgen receptor (AR) inhibitor Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

The company revealed that use of the combination “significantly improved the dual primary endpoints of overall survival (OS) and radiographic progression-free survival (rPFS)”.

Insider Interview: Paving paths in prostate cancer

Published on 16/05/19 at 11:39am

Joaquin Casariego Garcia Luben, Medical Affairs Director Europe, Middle East & Africa, Prostate Cancer for Johnson & Johnson (pictured) discusses Janssen’s vision in Oncology and how the company is building on its heritage in prostate cancer to deliver transformational outcomes for patient.

What is Janssen’s vision in oncology?

NICE turns down Astellas' Xtandi in prostate cancer

Astellas’ Xtandi (enzalutamide) has been rejected by UK medicines watchdog NICE for use on the NHS as a therapy for prostate cancer, it has emerged, meaning patients may need to wait until a later stage of their disease in order to access the drug on the health service.  

Xtandi was assessed in a study of 1,401 participants, with 933 patients with non-metastatic prostate cancer taking Astellas’ testosterone-blocking drug, with the rest taking placebo. It was found that the therapy improved progression-free survival by 36.6 months on average versus 14.7 months with placebo.

Astellas' Xtandi "significantly improves" progression-free survival in advanced hormone-sensitive prostate cancer

Japanese pharma firm Astellas has lifted the curtain on new data for its androgen receptor signalling inhibitor Xtandi (enzalutamide), when combined with androgen deprivation therapy (ADT), in the treatment of male patients with metastatic hormone-sensitive prostate cancer (mHSPC).

It was found that the combination met its primary endpoint in Phase 3 trials, significantly reducing the risk of radiographic progression or death by 61% compared to the combination of ADT and placebo.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches